Vertex announces european commission approval for symkevi® (tezacaftor/ivacaftor) with kalydeco® (ivacaftor) for eligible children with cystic fibrosis ages 6-11 years

London--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the european commission has granted approval of the label extension for symkevi® (tezacaftor/ivacaftor) with kalydeco® (ivacaftor), to include the treatment of cystic fibrosis (cf) in patients ages 6 years and older who have two copies of the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene or one copy of the f508del mutation and one copy of one of 14 mutations
VRTX Ratings Summary
VRTX Quant Ranking